Combination ATR and PARP Inhibitor (CAPRI): A phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-resistant epithelial ovarian cancer.

Shah, Payal D; Wethington, Stephanie L; Pagan, Cheyenne; Latif, Nawar; Tanyi, Janos; Martin, Lainie P; Morgan, Mark; Burger, Robert A; Haggerty, Ashley; Zarrin, Haley; Rodriguez, Diego; Domchek, Susan; Drapkin, Ronny; Shih, Ie-Ming; Smith, Simon A; Dean, Emma; Gaillard, Stéphanie; Armstrong, Deborah; Torigian, Drew A; Hwang, Wei-Ting; Giuntoli, Robert; Simpkins, Fiona

Shah, Payal D; Wethington, Stephanie L; Pagan, Cheyenne; Latif, Nawar; Tanyi, Janos; Martin, Lainie P; Morgan, Mark; Burger, Robert A; Haggerty, Ashley; Zarrin, Haley; Rodriguez, Diego; Domchek, Susan; Drapkin, Ronny; Shih, Ie-Ming; Smith, Simon A; Dean, Emma; Gaillard, Stéphanie; Armstrong, Deborah; Torigian, Drew A; Hwang, Wei-Ting; Giuntoli, Robert; Simpkins, Fiona.

Afiliación

Shah PD; Basser Center for BRCA, Perelman School of Medicine at the University of Pennsylvania, United States of America; Division of Medical Oncology, Perelman School of Medicine at the University of Pennsylvania, United States of America.
Wethington SL; The Kelly Gynecologic Oncology Service, Department of Gynecology and Obstetrics, Johns Hopkins Medicine, United States of America.
Pagan C; Division of Gynecology Oncology, Department of Obstetrics & Gynecology, Perelman School of Medicine at the University of Pennsylvania, United States of America.
Latif N; Division of Gynecology Oncology, Department of Obstetrics & Gynecology, Perelman School of Medicine at the University of Pennsylvania, United States of America.
Tanyi J; Division of Gynecology Oncology, Department of Obstetrics & Gynecology, Perelman School of Medicine at the University of Pennsylvania, United States of America.
Martin LP; Division of Medical Oncology, Perelman School of Medicine at the University of Pennsylvania, United States of America.
Morgan M; Division of Gynecology Oncology, Department of Obstetrics & Gynecology, Perelman School of Medicine at the University of Pennsylvania, United States of America.
Burger RA; Division of Gynecology Oncology, Department of Obstetrics & Gynecology, Perelman School of Medicine at the University of Pennsylvania, United States of America.
Haggerty A; Division of Gynecology Oncology, Department of Obstetrics & Gynecology, Perelman School of Medicine at the University of Pennsylvania, United States of America.
Zarrin H; Division of Gynecology Oncology, Department of Obstetrics & Gynecology, Perelman School of Medicine at the University of Pennsylvania, United States of America.
Rodriguez D; Division of Gynecology Oncology, Department of Obstetrics & Gynecology, Perelman School of Medicine at the University of Pennsylvania, United States of America.
Domchek S; Basser Center for BRCA, Perelman School of Medicine at the University of Pennsylvania, United States of America; Division of Medical Oncology, Perelman School of Medicine at the University of Pennsylvania, United States of America.
Drapkin R; Basser Center for BRCA, Perelman School of Medicine at the University of Pennsylvania, United States of America; Division of Gynecology Oncology, Department of Obstetrics & Gynecology, Perelman School of Medicine at the University of Pennsylvania, United States of America.
Shih IM; The Kelly Gynecologic Oncology Service, Department of Gynecology and Obstetrics, Johns Hopkins Medicine, United States of America.
Smith SA; AstraZeneca, R&D Oncology, Cambridge, UK.
Dean E; AstraZeneca, R&D Oncology, Cambridge, UK.
Gaillard S; The Kelly Gynecologic Oncology Service, Department of Gynecology and Obstetrics, Johns Hopkins Medicine, United States of America.
Armstrong D; The Kelly Gynecologic Oncology Service, Department of Gynecology and Obstetrics, Johns Hopkins Medicine, United States of America.
Torigian DA; Department of Radiology, Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania, United States of America.
Hwang WT; Division of Biostatistics, Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania, United States of America.
Giuntoli R; Division of Gynecology Oncology, Department of Obstetrics & Gynecology, Perelman School of Medicine at the University of Pennsylvania, United States of America.
Simpkins F; Division of Gynecology Oncology, Department of Obstetrics & Gynecology, Perelman School of Medicine at the University of Pennsylvania, United States of America. Electronic address: Fiona.Simpkins@pennmedicine.upenn.edu.

Gynecol Oncol ; 163(2): 246-253, 2021 11.

Article en En | MEDLINE | ID: mdl-34620496

Asunto(s)

Protocolos de Quimioterapia Combinada Antineoplásica/administración & dosificación; Indoles/efectos adversos; Morfolinas/efectos adversos; Recurrencia Local de Neoplasia/tratamiento farmacológico; Neoplasias Ováricas/tratamiento farmacológico; Ftalazinas/administración & dosificación; Piperazinas/administración & dosificación; Pirimidinas/efectos adversos; Sulfonamidas/efectos adversos; Administración Oral; Anciano; Protocolos de Quimioterapia Combinada Antineoplásica/efectos adversos; Proteínas de la Ataxia Telangiectasia Mutada/antagonistas & inhibidores; Proteína BRCA1/genética; Esquema de Medicación; Resistencia a Antineoplásicos; Femenino; Humanos; Indoles/administración & dosificación; Imagen por Resonancia Magnética; Persona de Mediana Edad; Morfolinas/administración & dosificación; Recurrencia Local de Neoplasia/mortalidad; Recurrencia Local de Neoplasia/patología; Neoplasias Ováricas/diagnóstico; Neoplasias Ováricas/genética; Neoplasias Ováricas/mortalidad; Ovario/diagnóstico por imagen; Ovario/patología; Ftalazinas/efectos adversos; Piperazinas/efectos adversos; Inhibidores de Poli(ADP-Ribosa) Polimerasas/administración & dosificación; Inhibidores de Poli(ADP-Ribosa) Polimerasas/efectos adversos; Supervivencia sin Progresión; Inhibidores de Proteínas Quinasas; Pirimidinas/administración & dosificación; Criterios de Evaluación de Respuesta en Tumores Sólidos; Sulfonamidas/administración & dosificación; Tomografía Computarizada por Rayos X

Palabras clave

ATR; Ceralasertib; Olaparib; Ovarian cancer; PARP; Platinum-resistant

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias Ováricas / Ftalazinas / Piperazinas / Pirimidinas / Sulfonamidas / Protocolos de Quimioterapia Combinada Antineoplásica / Morfolinas / Indoles / Recurrencia Local de Neoplasia Tipo de estudio: Diagnostic_studies Límite: Aged / Female / Humans / Middle aged Idioma: En Revista: Gynecol Oncol Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google